JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13
JP Morgan analyst Jessica Fye maintains BioCryst Pharma (NASDAQ:BCRX) with a Neutral and raises the price target from $12 to $13.
Share
Why It Matters
A big bank analyst thinks BioCryst is fairly priced but sees room to grow a bit. Watch if the company's medicines sell well and make money like the bank expects.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.